Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $280

Benzinga Newsdesk www.benzinga.com Positive 78.3%

Neg 0% Neu 0% Pos 78.3%

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $245 to $280.